 CAMBRIDGE, Mass., Feb. 23, 2022 GLOBE NEWSWIRE -- Jounce Therapeutics, Inc. NASDAQ: JNCE, a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report fourth quarter and full year 2021 financial results and provide a corporate update before market open on Wednesday, March 2, 2022. Jounce Therapeutics management team will host a live conference call and webcast at 8:00 a.m. ET. 